Alfa Laval and Lund University, one of Scandinavia's oldest and most prestigious academic institutions, have formalized a new strategic partnership to strengthen collaboration, drive innovation, and ...

Scientists found that gluten is key to spaghetti’s strength, acting like a microscopic safety net that prevents ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished ...

Pregnancies do not weaken a woman's skeleton. Breastfeeding, however, can reduce bone density considerably. These are ...

Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability ...

Canada will accelerate mining projects worth C$6.4 billion ($4.6 billion), as part of the Critical Minerals Production ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025.

An international team of researchers led by the Leibniz Institute for Astrophysics Potsdam (AIP) has shed light on a ...

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

Xintela (XINT) announces that the last patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of all ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025DynamX® ...

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma announced that its drug imlifidase successfully met the primary endpoint ...